CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Akebia’s Vadadustat Lowers Hospitalization Rate 10% Versus ESA in VOICE Trial

By Public Technologies
  • Akebia Therapeutics announced Oct. 26, 2026, that U.S. Renal Care presented favorable VOICE trial results at American Society of Nephrology Kidney Week.
  • The 2,116-patient trial found vadadustat reduced hospitalizations versus erythropoiesis-stimulating agents, with no significant difference in mortality.
  • Vadadustat recipients experienced fewer serious adverse events, more stable hemoglobin control and less need for rescue treatment.
  • The trial tested three-times-weekly dosing; Vafseo, the marketed form of vadadustat, is FDA-approved for once-daily use in eligible adults receiving dialysis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260920PRIMZONEFULLFEED9852976) on October 26, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.